FrancophonIA/ELRC3.0 huggingface dataset:
English: Cortisol is needed to control many body processes (including inflammation and the control of sugar and mineral levels) and is sometimes referred to as the ‘stress hormone' because it helps the body respond to stress.
Estonian: Kortisooli on vaja paljude organismi protsesside reguleerimiseks (sh põletiku ning suhkru- ja mineraalisisalduse reguleerimiseks); mõnikord nimetatakse seda stressihormooniks, sest see aitab organismil reageerida stressile.
English: As for every medicine, the company provided studies on the quality of Alkindi.
Estonian: Nagu iga ravimi korral, esitas ettevõte Alkindi kvaliteedi uuringud.
English: The European Medicines Agency concluded that the benefits of Alkindi are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Euroopa Ravimiamet järeldas, et Alkindi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: It must also not be used in children with difficulty swallowing or in premature babies who haven't started feeding by mouth.
Estonian: Samuti ei tohi seda kasutada neelamisraskustega lastel ega enneaegsetel imikutel, keda ei toideta veel suu kaudu.
English: The granules can also be sprinkled on a spoonful of soft food and given to the child immediately.
Estonian: Samuti võib graanulid puistata lusikatäiele pehmele toidule ja sööta see kohe lapsele.
English: A lack of the hormone causes several symptoms, including weight loss, muscle weakness, tiredness and low blood pressure.
Estonian: Selle hormooni vaegus põhjustab mitmesuguseid sümptomeid, näiteks kehakaalu vähenemine, lihasenõrkus, väsimus ja madal vererõhk.
English: Why is Alkindi approved?
Estonian: Miks Alkindi heaks kiideti?
English: The company also carried out studies to show that it is ‘bioequivalent' to the reference medicine.
Estonian: Ettevõte tegi ka uuringud, mis tõendasid ravimi bioekvivalentsust võrdlusravimiga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Alkindi have been included in the summary of product characteristics and the package leaflet.
Estonian: Alkindi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Studies on the benefits and risks of the active substance have already been carried out with the reference medicine and do not need to be repeated for Alkindi.
Estonian: Võrdlusravimiga on juba tehtud toimeaine kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Alkindi korrata.
English: Alkindi hydrocortisone
Estonian: Alkindi hüdrokortisoon
English: This means that it is similar to a ‘reference medicine' containing the same active substance (in this case Hydrocortisone Tablets Auden Mckenzie), but Alkindi is available in a different form (granules instead of tablets) and has been developed for children only.
Estonian: See tähendab, et Alkindi sarnaneb võrdlusravimiga (Hydrocortisone Tablets Auden Mckenzie), mis sisaldab sama toimeainet, kuid Alkindit turustatakse teises ravimvormina (graanulite, mitte tablettidena) ja see on välja töötatud kasutamiseks ainult lastel.
English: These include changes in behaviour, nausea, inflammation in the lining of the stomach and changes in blood potassium levels and excess acid in the blood.
Estonian: Need on näiteks käitumise muutused, iiveldus, gastriit (mao limaskesta põletik), vere kaaliumisisalduse muutused ja vere liigne happesus.
English: For the full list of side effects see the package leaflet.
Estonian: Kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Other information about Alkindi
Estonian: Muu teave Alkindi kohta
English: Alkindi is a medicine for children (from birth to up to 18 years of age) whose adrenal glands cannot make enough of a hormone called cortisol.
Estonian: Alkindi on ravim, mida kasutatakse lastel (alates sünnist kuni 18 aasta vanuseni), kelle neerupealistes ei teki piisavalt kortisooli (teatud hormoon).
English: What are the risks associated with Alkindi?
Estonian: Mis riskid Alkindiga kaasnevad?
English: Alkindi produces similar levels of hydrocortisone in the blood to a reference medicine already authorised in the EU.
Estonian: Alkindi tekitab veres sarnase hüdrokortisoonisisalduse nagu võrdlusravim, millel juba on Euroopa Liidus müügiluba.
English: This is a summary of the European public assessment report (EPAR) for Alkindi.
Estonian: See on ravimi Alkindi Euroopa avaliku hindamisaruande kokkuvõte.
English: How is Alkindi used?
Estonian: Kuidas Alkindit kasutatakse?
English: No side effects were reported in studies with Alkindi, but some side effects have been reported with other hydrocortisone medicines.
Estonian: Alkindi uuringutes kõrvalnähtudest ei teatatud, kuid muude hüdrokortisoonravimite korral on teatatud mõnest kõrvalnähust.
English: It is not intended to provide practical advice on how to use Alkindi.
Estonian: Hindamisaruandes ei anta Alkindi kasutamise praktilisi nõuandeid.
English: How does Alkindi work?
Estonian: Kuidas Alkindi toimib?
English: Alkindi is a ‘hybrid medicine'.
Estonian: Alkindi on hübriidravim.
English: Hydrocortisone replaces the natural cortisol that is missing in children whose adrenal glands do not produce enough of the hormone, thereby helping to relieve their symptoms.
Estonian: Lastel, kelle neerupealistes ei teki piisavalt kortisooli, asendab hüdrokortisoon seda organismis puuduvat hormooni, aidates leevendada sümptomeid.
English: For practical information about using Alkindi, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Alkindi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: What benefits of Alkindi have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Alkindi kasulikkus?
English: Alkindi contains the active substance hydrocortisone.
Estonian: Alkindi sisaldab toimeainena hüdrokortisooni.
English: The active substance in Alkindi, hydrocortisone, is the same as cortisol, the main steroid hormone released by the body's adrenal gland.
Estonian: Alkindi toimeaine hüdrokortisoon on sama kui organismis neerupealistes tekkiv peamine steroidhormoon kortisool.
English: Alkindi is also available in a form suitable for children and it is easier to give a precise dose with Alkindi than with other treatments which require crushing tablets and weighing up the right dose.
Estonian: Samuti turustatakse Alkindit lastele sobivas ravimvormis ning Alkindiga on täpse annuse andmine lihtsam kui tablettide korral, sest need tuleb purustada ja seejärel kaaluda õige annus.
English: Alkindi is available as capsules containing granules.
Estonian: Alkindit turustatakse graanuleid sisaldavate kapslitena.
English: Alkindi must not be used in patients with hypersensitivity (allergy) to the active substance or to any of the ingredients of Alkindi.
Estonian: Ravimit ei tohi kasutada patsiendid, kes on toimeaine või Alkindi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: For more information about treatment with Alkindi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Alkindiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The medicine can only be obtained with a prescription.
Estonian: Alkindi on retseptiravim.
English: on 9 August 2002.
Estonian: 9. augustil 2002.
English: The studies were performed according to the requirements of the appropriate European Pharmacopoeia monographs.
Estonian: Uuringud tehti Euroopa farmakopöa asjakohaste monograafiate nõudeid järgides.
English: The onset of protection is from 2 weeks onwards and the protection extends to 9 weeks.
Estonian: Immuunsus tekib 2 nädala pärast ja kestab 9 nädalat.
English: It is therefore recommended that no other vaccine than these should be administered within 14 days after vaccination with the product.
Estonian: Seetõttu ei ole soovitatav manustada teisi vaktsiine 14 päeva pärast selle tootega vaktsineerimist.
English: The vaccine is also effective against Marek's disease.
Estonian: Vaktsiin toimib ka Mareki haiguse vastu.
English: Studies have shown that the strain appears safe for turkeys, however precautionary measures should be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.
Estonian: Uuringud on näidanud, et see tüvi näib olevat kalkunitele ohutu, kuid tuleb võtta ettevaatusmeetmeid vaktsineeritud tibude ja kalkunite vaheliste otsese ja kaudse kokkupuute vältimiseks.
English: This summary was last updated in July 2007.
Estonian: Kokkuvõtte viimane uuendus: 07-2007.
English: Whilst the vaccine is unlikely to affect male fertility, a warning has nevertheless been included in the SPC.
Estonian: Kuigi vaktsiin meeste viljakust tõenäoliselt ei mõjuta, on ravimi omaduste kokkuvõttesse lisatud siiski sellekohane hoiatus.
English: No information is available on the safety and efficacy from the concurrent use with any other vaccine, except Merial attenuated vaccines against Marek's disease, Newcastle disease and Infectious bronchitis.
Estonian: Puuduvad andmed vaktsiini ohutuse ja efektiivsuse kohta preparaadi samaaegsel kasutamisel koos teiste vaktsiinidega, välja arvatud Meriali nõrgestatud vaktsiinid Mareki haiguse, Newcastle'i haiguse ja nakkusliku bronhiidi vastu.
English: The onset of protection is from 4 days onwards.
Estonian: Immuunsus tekib 4 päeva pärast.
English: The safety of the product has been demonstrated in several laboratory and field trials in specific pathogen-free and other chickens.
Estonian: Ravimi ohutust tõendati mitme laboratoorse ja välikatsega, mis sooritati konkreetsetest patogeenidest vabade ja muude kanatibudega.
English: The safety for non-susceptible bird species (pheasants, ducks, partridges, quails and pigeons) and for mammalian species (mice and guinea-pigs) was also demonstrated.
Estonian: Tõendati ka vaktsiini ohutust sellele mittetundlikele linnuliikidele (faasan, part, põldpüü, põldvutt ja tuvi) ning imetajaliikidele (hiir ja merisiga).
English: A single vaccination is sufficient to provide protection during the risk period.
Estonian: Immuunsuse tekkimiseks ohtlikul perioodil piisab ühekordsest vaktsineerimisest.
English: Only healthy birds should be vaccinated and the product should not be used in birds in lay and breeding birds.
Estonian: Vaktsineerida tohib ainult terveid linde ning vaktsiini ei tohi kasutada munevatel ja sugulindudel.
English: As for any turkey Herpesvirus (HVT) live vaccine, the product is excreted from vaccinated birds and may spread to turkeys.
Estonian: Nagu kõik kalkuni herpesviiruse (HVT) elusvaktsiinid, eritub vaktsiin vaktsineeritud lindudelt ja võib edasi levida kalkunutele.
English: It is presented as a frozen suspension to be reconstituted with diluent and injected into chickens and into eggs where chicks are developing.
Estonian: Seda turustatakse külmutatud suspensioonina, mis lahjendatakse lahjendiga ja süstitakse kanatibudele ning lootega kanamunadesse.
English: The product appears to show no interference with antibodies derived from the mother bird and can be safely administered to day-old chickens and chicks in the egg without presenting any apparent safety problem or inducing an immunosuppressive effect.
Estonian: Ravim ei häiri emalinnult saadud antikehade teket ja seda võib ohutult manustada ühepäevastele kanatibudele ja lootega kanamunadesse, ilma et tekiks ohutuseprobleeme või immuunsust vähendavat toimet.
English: In the absence of specific studies, no other vaccine should be administered at the same time when the product is injected into eggs.
Estonian: Eriuuringute puudumise tõttu ei tohi munasse vaktsineerimise korral kasutada samaaegselt teisi vaktsiine.
English: Vaxxitek HVT + IBD contains vaccine strains which induce an active immunity and a serological response (detected antibodies) against the two diseases.
Estonian: Vaxxitek HVT+IBD sisaldab vaktsiinitüvesid, mis tekitavad aktiivse immuunsuse ja seroloogilise vastuse (antikehade) tekke nende kahe haiguse vastu.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Vaxxitek HVT+IBD exceed the risks of its use in chickens and recommended that Vaxxitek HVT+IBD be given a marketing authorisation.
Estonian: Veterinaarravimite komitee otsustas, et Vaxxitek HVT+IBD soodne toime selle kasutamisel kanadel on suurem kui sellega kaasnevad riskid, ning Vaxxitek HVT+IBD-le soovitati anda müügiluba.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) VAXXITEK HVT+IBD EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE VAXXITEK HVT+IBD Kokkuvõte üldsusele
English: The studies demonstrated that Vaxxitek HVT+IBD is effective in the active immunisation of chickens and chicks in the egg against Infectious Bursal disease.
Estonian: Uuringud näitasid, et Vaxxitek HVT+IBD on efektiivne kanatibude ja munas olevate kanaloodete aktiivseks immuniseerimiseks nakkusliku bursiidi vastu.
English: As the product is stored in a tank under liquid nitrogen, particular instructions for reconstitution of the vaccine are provided in the product information module of the EPAR.
Estonian: Vaktsiini säilitatakse vedelas lämmastikus ning erijuhised vaktsiini valmistamiseks on esitatud Euroopa avaliku hindamisaruande ravimiteabe jaotises.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Vaxxitek HVT+IBD to Merial S.A.S.
Estonian: Euroopa Komisjon väljastas Vaxxitek HVT+IBD müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Merial S.A.S.
English: Vaxxitek HVT+IBD is a recombinant vaccine intended for use against Infectious Bursal Disease (also known as Gumboro Disease) and Marek's Disease in chickens.
Estonian: Vaxxitek HVT+IBD on rekombinantne vaktsiin kanatibude immuniseerimiseks nakkusliku bursiidi (IBD ehk Gumboro haiguse) ja Mareki haiguse vastu.
English: Other information about Vaxxitek HVT+IBD:
Estonian: Muu teave Vaxxitek HVT+IBD kohta
English: Vaxxitek HVT+IBD is also used to reduce mortality, clinical signs and effects of Marek's disease, a herpes virus infection of chickens.
Estonian: Vaxxitek HVT+IBD-d kasutatakse ka Mareki haigusest (kanade teatud herpesviirusnakkusest) põhjustatud suremuse, kliiniliste nähtude ja mõjude vähendamiseks.
English: Vaxxitek HVT+IBD is used to prevent the deaths of chickens and to reduce clinical signs and effects of Infectious Bursal disease which is a disease which damages the immune system of chickens.
Estonian: Vaxxitek HVT+IBD-d kasutatakse kanatibude suremuse vältimiseks ja kanatibude immuunsüsteemi kahjustava nakkusliku bursiidi kliiniliste tunnuste ja mõju vähendamiseks.
English: What is Vaxxitek HVT+IBD?
Estonian: Mis on Vaxxitek HVT+IBD?
English: Why has Vaxxitek HVT+IBD been approved?
Estonian: Miks Vaxxitek HVT+IBD heaks kiideti?
English: What is the risk associated with Vaxxitek HVT+IBD?
Estonian: Millised on Vaxxitek HVT+IBD-ga kaasnevad riskid?
English: How does Vaxxitek HVT+IBD work?
Estonian: Kuidas Vaxxitek HVT+IBD toimib?
English: What is Vaxxitek HVT+IBD used for?
Estonian: Milleks Vaxxitek HVT+IBD-d kasutatakse?
English: How has Vaxxitek HVT+IBD been studied?
Estonian: Kuidas Vaxxitek HVT+IBD efektiivsust uuriti?
English: What benefit has Vaxxitek HVT+IBD shown during the studies?
Estonian: Milles seisneb uuringute põhjal Vaxxitek HVT+IBD kasulikkus?
English: Other information about Pritor
Estonian: Muu teave Pritori kohta
English: What measures are being taken to ensure the safe and effective use of Pritor?
Estonian: Mis meetmed võetakse, et tagada Pritori ohutu ja efektiivne kasutamine?
English: The full EPAR for Pritor can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Pritori kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: A risk management plan has been developed to ensure that Pritor is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Pritori võimalikult ohutu kasutamine.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pritor on 11 December 1998.
Estonian: Euroopa Komisjon andis Pritori müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 11. detsembril
English: Pritor telmisartan
Estonian: Pritor telmisartaan
English: However, the following side effects are seen in between 1 and 10 patients in 1,000: upper respiratory tract infection (colds) including inflammation of the throat and sinuses, urinary tract infection (infection of the structures that carry urine) including bladder infection, anaemia (low red blood cell counts), hyperkalaemia (high blood potassium levels), depression, insomnia (difficulty sleeping), syncope (fainting), vertigo (a spinning sensation), bradycardia (slow heart rate), hypotension (low blood pressure), dyspnoea (difficulty breathing), cough, abdominal pain (stomach ache), diarrhoea, dyspepsia (heartburn), flatulence (gas), vomiting, hyperhidrosis (excessive sweating), pruritus (itching), rash, myalgia (muscle pain), back pain, muscle spasms, renal impairment
Estonian: 1-10 patsiendil 1000st on siiski esinenud järgmised kõrvalnähud: ülemiste hingamisteede nakkus (külmetus), sh kõri- ja ninakõrvalurgete põletik, kuseteede infektsioon, sh põieinfektsioon, aneemia (vere punaliblede vähesus), hüperkaleemia (vere liigne kaaliumisisaldus), depressioon, unetus, sünkoop (minestus), vertiigo (peapööritus), bradükardia (südameaeglus), hüpotensioon (madal vererõhk), düspnoe (raskendatud hingamine), köha, kõhuvalu, kõhulahtisus, düspepsia (kõrvetised), kõhupuhitus, oksendamine, hüperhidroos (liighigistamine), kihelus, lööve, müalgia (lihasevalu), seljavalu, lihasekrambid, neerupuudulikkus, sh äkiline neerupuudulikkus, rindkerevalu, asteenia (nõrkus) ja kreatiniini (lihaskoe lagunemise marker) suurenenud sisaldus veres.
English: Pritor is a medicine that contains the active substance telmisartan.
Estonian: Pritor on ravim, mis sisaldab toimeainena telmisartaani.
English: The doctor should monitor the patient's blood pressure closely when starting Pritor, and may decide to adjust the patient's blood pressure-lowering medication.
Estonian: Arst peab Pritori ravi alguses tähelepanelikult jälgima patsiendi vererõhku ning ta võib otsustada vererõhku vähendavat annust kohandada.
English: Hypotension may be more common in patients receiving Pritor to prevent cardiovascular problems.
Estonian: Hüpotensioon võib sagedamini esineda patsientidel, kes võtavad Pritorit kardiovaskulaarhäirete ennetamiseks.
English: The CHMP decided that Pritor's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Pritori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: What is the risk associated with Pritor?
Estonian: Mis riskid Pritoriga kaasnevad?
English: In patients with type 2 diabetes or in patients with moderate or severe kidney impairment, Pritor must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension).
Estonian: II tüüpi diabeediga patsiendid või mõõduka kuni raske neerukahjustusega patsiendid ei tohi Pritorit kasutada koos aliskireeni sisaldavate ravimitega (samuti essentsiaalse hüpertensiooni ravimid).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pritor, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Pritori omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For more information about treatment with Pritor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pritoriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For the prevention of cardiovascular problems, 80 mg Pritor once a day has been studied in one main study involving almost 26,000 patients aged 55 years or over who had heart or artery disease, had had a stroke, or had diabetes and were at high risk of cardiovascular problems.
Estonian: Kardiovaskulaarhäirete ennetamiseks uuriti üks kord ööpäevas manustatava 80 mg Pritori annuse mõju ühes põhiuuringus, milles osales ligikaudu 26 000 vähemalt 55-aastast patsienti, kellel oli südame- või arterite haigus, oli olnud infarkt või kellel oli diabeet ja kardiovaskulaarhäirete suur risk.
English: Various doses of Pritor were compared with placebo (a dummy treatment) and with other medicines for hypertension (atenolol, lisinopril, enalapril and amlodipine).
Estonian: Pritori eri annuste toimet võrreldi platseebo (näiva ravimi) ja teiste kõrgvererõhuravimite (atenolool, lisinopriil, enalapriil, amlodipiin) toimega.
English: What is Pritor?
Estonian: Mis on Pritor?
English: Pritor was compared with ramipril (another medicine to prevent cardiovascular problems), and with the combination of both medicines.
Estonian: Pritori toimet võrreldi ramipriili toimega (samuti kardiovaskulaarhäirete ennetamise ravim) ja mõlema ravimi koostoimega.
English: The active substance in Pritor, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Pritori toimeaine telmisartaan on angiotensiin II retseptori antagonist, mis blokeerib organismi hormooni angiotensiin II toime.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pritor.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: This is a summary of the European public assessment report (EPAR) for Pritor.
Estonian: See on ravimi Pritor Euroopa avaliku hindamisaruande kokkuvõte.
English: For the treatment of essential hypertension, the usual recommended dose of Pritor is 40 mg once a day, but some patients may benefit from using 20 mg once a day.
Estonian: Essentsiaalse hüpertensiooni raviks on tavaline soovitatav Pritori annus 40 mg üks kord ööpäevas, kuid mõnele patsiendile võib piisata ka annusest 20 mg üks kord ööpäevas.
English: Why has Pritor been approved?
Estonian: Miks Pritor heaks kiideti?
English: Pritor must not be used in people who have severe liver problems or bile problems.
Estonian: Pritorit ei tohi kasutada ka patsiendid, kellel on rasked maksa- või sapihäired.
English: For the treatment of essential hypertension, Pritor has been studied in 2,647 patients who took Pritor either alone or in combination with hydrochlorothiazide.
Estonian: Essentsiaalse hüpertensiooni ravis uuriti Pritorit 2647 patsiendil, kes võtsid kas ainult Pritorit või Pritorit koos hüdroklorotiasiidiga.
English: In the treatment of essential hypertension, Pritor was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
Estonian: Essentsiaalse hüpertensiooni ravis oli Pritor diastoolse vererõhu vähendamisel efektiivsem kui platseebo ning ravimi toime kõrgvererõhule sarnanes teiste kõrgvererõhuravimite toimega.
English: In the prevention of cardiovascular problems, Pritor had a similar effect to ramipril, with around 17% of patients dying, being admitted to hospital because of cardiovascular problems, or having a heart attack or stroke.
Estonian: Kardiovaskulaarhäirete ennetamisel sarnanes Pritori toime ramipriili toimega: ligikaudu 17% patsientidest suri, vajas kardiovaskulaarhäirete tõttu haiglaravi või sai südameinfarkti või insuldi.